GlassScriptPhysician profile
Quimberly Thomas
NPI 1891335113
$412.75
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $16.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $137.27 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $33.68 | 2021 | |
| Eisai INC. | $31.71 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.28 | 2021 | |
| Daiichi Sankyo INC. | $19.16 | 2021 | |
| Genentech USA, INC. | $18.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.09 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.45 | 2021 | |
| Merck Sharp & Dohme LLC | $17.41 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.95 | 2021 | |
| Novo Nordisk INC | $14.87 | 2021 | |
| Bausch Health US, LLC | $14.63 | 2021 | |
| Hologic Sales and Service, LLC | $14.46 | 2021 | |
| Amgen INC. | $14.21 | 2021 | |
| Lilly USA, LLC | $13.60 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quimberly Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.